文献速递头颈外科

可切除头颈鳞癌新辅助PD-1/PD-L1抑制剂系统评价与Meta分析

Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2021-01-01

该系统评价与Meta分析纳入10项研究共344例可切除HNSCC患者,评估新辅助PD-1/PD-L1抑制剂疗效与安全性。仅免疫治疗研究中原发灶主要病理缓解率9.7%(95%CI 3.1%-18.9%),病理完全缓解率2.9%(95%CI 0%-9.5%),术前3-4级治疗相关不良事件8.4%(95%CI 0.2%-23.2%),手术延迟率0%(95%CI 0%-0.9%)。新辅助免疫治疗耐受良好,病理缓解提示潜在获益,长期结局待随访。

要点

  • 可切除HNSCC新辅助PD-1/PD-L1抑制剂总体耐受良好,手术延迟率低。
  • 仅免疫治疗时原发灶MPR率9.7%、pCR率2.9%,病理缓解提示潜在获益。
  • 未发现某一种抗PD-1/PD-L1药物优于另一种,联合抗CTLA-4亦显示 favorable association。

核心结论

  • 可切除HNSCC新辅助抗PD-1/PD-L1免疫治疗耐受良好,组织病理学缓解提示可能带来治疗优势,长期结局尚待随访。

研究设计与样本

  • 系统评价与Meta分析,系统检索PubMed(MEDLINE)、Embase、Cochrane Library和ClinicalTrials.gov,纳入2015年至2021年7月发表的队列研究和随机临床试验。
  • 共纳入10项研究、344例患者;其中8项仅给予新辅助免疫治疗,2项联合新辅助化疗和/或放疗。
  • 采用随机和固定模型计算合并比值比,所有结果以95%CI呈现,并使用Cochrane协作网偏倚风险工具评估数据质量。

主要发现

  • 仅新辅助免疫治疗研究中,原发灶主要病理缓解率为9.7%(95%CI 3.1%-18.9%),病理完全缓解率为2.9%(95%CI 0%-9.5%)。
  • 术前3-4级治疗相关不良事件发生率为8.4%(95%CI 0.2%-23.2%),手术延迟率为0%(95%CI 0%-0.9%)。
  • 新辅助免疫治疗与所有结局指标呈有利关联;亚组分析未发现某一种抗PD-1/PD-L1药物优于另一种,单用免疫治疗或联合抗CTLA-4均显示有利关联。

关键数值与推荐

  • 主要结局为疗效(原发灶和淋巴结分别评估主要病理缓解和病理完全缓解)与安全性(术前3-4级治疗相关不良事件和手术延迟率)。

临床怎么用

  • 对于可切除HNSCC,新辅助PD-1/PD-L1抑制剂可作为耐受性良好的治疗选择,病理缓解结果支持其潜在获益,但需结合长期结局等待进一步证据。

局限性

  • 纳入研究数量有限(10项),部分研究联合了新辅助化疗和/或放疗,仅免疫治疗亚组样本量较小,长期生存结局尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The emerging approach of neoadjuvant immunotherapy for solid cancers has set the ground for the integration of programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) inhibitors into the neoadjuvant setting of head and neck squamous cell carcinoma (HNSCC) treatment. OBJECTIVE: To assess the reported efficacy and safety of neoadjuvant immunotherapy for resectable HNSCC. DATA SOURCES AND STUDY SELECTION: Electronic databases, including PubMed (MEDLINE), Embase, the Cochrane Library, and ClinicalTrials.gov were systematically searched for published and ongoing cohort studies and randomized clinical trials that evaluate neoadjuvant immunotherapy for resectable HNSCC. The search results generated studies from 2015 to July 2021. DATA EXTRACTION AND SYNTHESIS: Two investigators (R.M. and L.K.) independently identified and extracted articles for potential inclusion. Random and fixed models were used to achieve pooled odds ratios. All results are presented with 95% CIs. Data quality was assessed by means of the Cochrane Collaboration's risk of bias tool. MAIN OUTCOMES AND MEASURES: The primary outcomes were reported efficacy, evaluated by major pathological response and pathological complete response in the primary tumors and lymph nodes separately, and safety, assessed by preoperative grade 3 to 4 treatment-related adverse events and surgical delay rate. RESULTS: A total of 344 patients from 10 studies were included. In 8 studies, neoadjuvant immunotherapy only was administered, and the other 2 studies combined immunotherapy with neoadjuvant chemotherapy and/or radiotherapy. The overall major pathological response rate in the primary tumor sites from studies reporting on neoadjuvant immunotherapy only was 9.7% (95% CI, 3.1%-18.9%) and the pathological complete response rate was 2.9% (95% CI, 0%-9.5%). Preoperative grade 3 to 4 treatment-related adverse events were reported at a rate of 8.4% (95% CI, 0.2%-23.2%) and surgical delay at a rate of 0% (95% CI, 0%-0.9%). There was a favorable association of neoadjuvant immunotherapy with all outcome measures. The subgroup analyses did not find one specific anti-PD-1/PD-L1 agent to be superior to another, and the favorable association was demonstrated by either immunotherapy alone or in combination with anti-CTLA-4. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, neoadjuvant anti-PD-1/PD-L1 immunotherapy for resectable HNSCC was well tolerated and may confer therapeutic advantages implied by histopathological response. Long-term outcomes are awaited.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Masarwy R, Kampel L, Horowitz G, et al. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021. PMID: 34473219. doi:10.1001/jamaoto.2021.2191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。